HUTCHMED

Edison Investment Research is terminating coverage on HUTCHMED. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Equities

Equities by Sector

Sectors

Thematics

Latest

Healthcare-focused trusts: A sector on the mend

MediaWatch – One step forward, two steps back

ConsumerWatch – Don’t look down

Audiovisual

Latest

Recce Pharmaceuticals – executive interview

VEON – executive interview with CFO Joop Brakenhoff

VEON – executive interview with CEO Kaan Terzioğlu

About Edison

About Edison

Careers

HUTCHMED (US: HCM)

Latest Insights

Hutchison China MediTech — A rolling stone gathers no moss

Hutchison China MediTech — A rolling stone gathers no moss

Hutchison China MediTech — To China and beyond

Hutchison China MediTech — To China and beyond

Sector

Share Price Performance

Financials

Research

Hutchison China MediTech — From innovation to oncology commercialisation

Hutchison China MediTech — 2020 insights into a breakout year

Hutchison China MediTech — From innovation to oncology commercialization

Hutchison China MediTech — Elunate receives China NRDL inclusion

Hutchison China MediTech — Elunate receives China NRDL inclusion

Hutchison China MediTech — Surufatinib NETs solid data at ESMO

Hutchison China MediTech — Surufatinib NETs solid data at ESMO

Hutchison China MediTech — Onwards and upwards

Hutchison China MediTech — Onwards and upwards

Hutchison China MediTech — An emerging global biopharma

Hutchison China MediTech — An emerging global biopharma

Hutchison China MediTech — Fruquintinib capsules approved in China

Hutchison China MediTech — Establishing a global operational presence

Hutchison China MediTech — Establishing a global operational presence

Hutchison China MediTech — Jewels in the crown

Hutchison China MediTech — WCLC highlights savolitinib combination potential

Hutchison China MediTech — WCLC highlights savolitinib combination potential

Hutchison China MediTech — ASCO data set up fruquintinib for China launch

Hutchison China MediTech — Future stars are aligning

Hutchison China MediTech — Future stars are aligning

Hutchison China MediTech — Update 28 February 2017

Hutchison China MediTech — Update 27 February 2017

Hutchison China MediTech — Update 12 December 2016

Hutchison China MediTech — Update 9 December 2016

Hutchison China MediTech — Update 27 May 2016

Hutchison China MediTech — Update 27 May 2016

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Seven things every investor should know about SIGA technologies & biological weapons

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Edison healthcare quarterly: A boost for allergy immunotherapy